MX2020008613A - Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. - Google Patents
Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.Info
- Publication number
- MX2020008613A MX2020008613A MX2020008613A MX2020008613A MX2020008613A MX 2020008613 A MX2020008613 A MX 2020008613A MX 2020008613 A MX2020008613 A MX 2020008613A MX 2020008613 A MX2020008613 A MX 2020008613A MX 2020008613 A MX2020008613 A MX 2020008613A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- tissue factor
- drug conjugates
- treatment
- factor antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
La invención proporciona métodos y composiciones para tratar el cáncer, tal como cáncer colorrectal, cáncer pulmonar de células no pequeñas, cáncer pancreático, cáncer de cabeza y cuello, cáncer de vejiga, cáncer endometrial, cáncer esofágico y cáncer de próstata, en un sujeto, tal como mediante la administración de conjugados de anticuerpofármaco que se enlazan al tejido tisular (TF). La invención también proporciona artículos de manufactura y composiciones que comprenden los conjugados de anticuerpo-fármaco que se enlazan al TF para el uso en el tratamiento del cáncer (por ejemplo, cáncer colorrectal, cáncer pulmonar de células no pequeñas, cáncer pancreático, cáncer de cabeza y cuello, cáncer de vejiga, cáncer endometrial, cáncer esofágico y cáncer de próstata).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862639891P | 2018-03-07 | 2018-03-07 | |
US201862736343P | 2018-09-25 | 2018-09-25 | |
PCT/US2019/021024 WO2019173523A1 (en) | 2018-03-07 | 2019-03-06 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008613A true MX2020008613A (es) | 2020-09-21 |
Family
ID=67845742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008613A MX2020008613A (es) | 2018-03-07 | 2019-03-06 | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210030888A1 (es) |
EP (1) | EP3762032A4 (es) |
JP (2) | JP7471227B2 (es) |
KR (1) | KR20200130356A (es) |
CN (1) | CN112105388A (es) |
AU (1) | AU2019231696A1 (es) |
BR (1) | BR112020018092A2 (es) |
CA (1) | CA3091217A1 (es) |
IL (1) | IL276768A (es) |
MX (1) | MX2020008613A (es) |
SG (1) | SG11202007865VA (es) |
WO (1) | WO2019173523A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023005930A (es) * | 2020-11-26 | 2023-05-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon. |
CN114569734B (zh) * | 2022-01-17 | 2023-08-29 | 北京化工大学 | 一种基于还原敏感聚合物递送阳离子铂药的纳米粒的制备方法 |
WO2023213960A1 (en) * | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
WO2024067864A1 (en) * | 2022-09-30 | 2024-04-04 | Shanghai Junshi Biosciences Co., Ltd. | Anti-lair1 antibodies and their uses |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106084053B (zh) * | 2010-06-15 | 2020-01-17 | 根马布股份公司 | 针对组织因子的人抗体药物缀合物 |
DK3347054T3 (da) * | 2015-09-11 | 2021-07-19 | Genmab As | Dosisregimer til anti-TF-antistoflægemiddelkonjugater |
-
2019
- 2019-03-06 US US16/978,539 patent/US20210030888A1/en active Pending
- 2019-03-06 BR BR112020018092-0A patent/BR112020018092A2/pt unknown
- 2019-03-06 WO PCT/US2019/021024 patent/WO2019173523A1/en unknown
- 2019-03-06 JP JP2020546443A patent/JP7471227B2/ja active Active
- 2019-03-06 CN CN201980031334.6A patent/CN112105388A/zh active Pending
- 2019-03-06 EP EP19764722.5A patent/EP3762032A4/en active Pending
- 2019-03-06 AU AU2019231696A patent/AU2019231696A1/en active Pending
- 2019-03-06 CA CA3091217A patent/CA3091217A1/en active Pending
- 2019-03-06 KR KR1020207028401A patent/KR20200130356A/ko unknown
- 2019-03-06 SG SG11202007865VA patent/SG11202007865VA/en unknown
- 2019-03-06 MX MX2020008613A patent/MX2020008613A/es unknown
-
2020
- 2020-08-17 IL IL276768A patent/IL276768A/en unknown
-
2024
- 2024-01-12 JP JP2024002970A patent/JP2024045219A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL276768A (en) | 2020-10-29 |
CA3091217A1 (en) | 2019-09-12 |
EP3762032A1 (en) | 2021-01-13 |
SG11202007865VA (en) | 2020-09-29 |
AU2019231696A1 (en) | 2020-09-03 |
CN112105388A (zh) | 2020-12-18 |
JP7471227B2 (ja) | 2024-04-19 |
BR112020018092A2 (pt) | 2020-12-22 |
JP2024045219A (ja) | 2024-04-02 |
US20210030888A1 (en) | 2021-02-04 |
WO2019173523A1 (en) | 2019-09-12 |
EP3762032A4 (en) | 2021-12-22 |
KR20200130356A (ko) | 2020-11-18 |
JP2021515017A (ja) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008613A (es) | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. | |
PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
CY1124628T1 (el) | Συζευγματα αντισωματος-φαρμακου βασει εριβουλινης και μεθοδοι χρησεως | |
PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
JO3291B1 (ar) | الأجسام المضادة لـ csf-1r | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
MX2016010127A (es) | Conjugados de anticuerpo-farmaco e inmunotoxinas. | |
WO2015118031A3 (en) | Antibody-drug conjugates and immunotoxins | |
MX2019007801A (es) | Tratamiento de cáncer avanzado con expresión de her2. | |
MX2022005221A (es) | Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso. | |
PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
NZ764878A (en) | Human monoclonal antibodies to ganglioside gd2 | |
EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
MX2020005473A (es) | Anticuerpos humanizados que se dirigen al factor tisular humano. | |
BR112013007327A2 (pt) | anticorpo quimérico isolado, polipeptídeo isolado, vetor de expressão, célula, métodos para produzir o anticorpo quimérico, para reduzir o crescimento e/ou a capacidade de invasão de uma célula neoplástica, para tratar um indivíduo que tem uma neoplasia, e para tratar ou prevenir a progressão de tumor ou metástase, composição farmacêutica, e, kit | |
MX2021001058A (es) | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer. | |
MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. | |
MX2022014231A (es) | Conjugados de anticuerpo-farmaco que se enfocan a la uparap. | |
EA202091688A1 (ru) | Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака | |
MX2021004045A (es) | Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco. | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. |